Russ Conroy

Zanzalintinib combined with atezolizumab significantly improves overall survival in metastatic colorectal cancer compared to regorafenib, offering new hope for patients.

Adjuvant therapy shows promise in achieving ctDNA clearance in colorectal cancer patients, correlating with improved disease-free survival outcomes.

Tarlatamab-dlle shows significant overall survival benefits over chemotherapy in small cell lung cancer, even in platinum-resistant cases.

Belzutifan shows improved quality-adjusted survival in advanced renal cell carcinoma compared with everolimus, enhancing patient quality of life and treatment outcomes.

Pembrolizumab and lenvatinib show promising survival rates and durable responses in advanced non-clear cell renal cell carcinoma, transforming treatment standards.

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk patients.

A prophylactic dermatologic regimen significantly reduced skin side effects and improved quality of life for NSCLC patients on amivantamab/lazertinib.

Most CRS, ICANS, and neuro events after liso-cel were mild and occurred within 15 days post-infusion, according to different clinical trial and real-world settings.

T-DXd plus pertuzumab significantly extended PFS (40.7 vs 26.9 months) in HER2+ metastatic breast cancer, suggesting a new frontline standard of care.

The NeoSTAR trial showed neoadjuvant sacituzumab govitecan and pembrolizumab achieved a 32% pCR rate in early-stage TNBC, with promising efficacy and a tolerable safety profile.

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C colorectal cancer.

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.

Prostatectomy for grade group 1 prostate cancer significantly decreased from 2010 to 2024 in SEER and MUSIC data. Remaining cases show more high-risk features.

Lenvatinib plus pembrolizumab showed activity and a favorable safety profile in nonmetastatic clear cell renal cell carcinoma, per phase 2 study results.

Datopotamab deruxtecan showed promising activity in advanced urothelial cancer in a phase 1 study.

Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.

Nivolumab plus ipilimumab significantly improved PFS over nivolumab alone in dMMR/MSI-H metastatic CRC in the CheckMate 8HW trial.

Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, per phase 2 trial data.

TACE with camrelizumab and rivoceranib significantly improves PFS in unresectable HCC, per phase 2 CARES-005 study results.

Trastuzumab with chemotherapy showed numerical improvements in overall survival and progression-free survival in HER2-positive gastric and gastroesophageal junction cancers.

Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.

At the 2024 ASH Annual Meeting, findings suggested that the IPSS-del(5q) Scoring System may more effectively identify risks in MDS with isolated 5q deletions compared to standard MDS scoring systems.

Immediate surgery significantly lowered local recurrence rates in elderly patients with breast cancer compared with delayed surgery, according to a meta-analysis presented at SABCS 2024.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated multiple myeloma, with high response rates and durable responses.